Shiro Kimbara

Kobe, 6500017, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Incidence of Cancer-Associated Venous Thromboembolism in Patients With Solid Cancers in Japan　- A Prospective Study.

Incidence of Cancer-Associated Venous Thromboembolism in Patients With Solid Cancers in Japan　- A Prospective Study.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: August 19, 2026

CUX1::MET fusion defines an indolent subtype of diffuse low-grade glioma, MAPK pathway-altered.

CUX1::MET fusion defines an indolent subtype of diffuse low-grade glioma, MAPK pathway-altered.

Journal: Acta neuropathologica communications

Published: January 13, 2026

A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.

A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer.

Journal: Japanese journal of clinical oncology

Published: October 11, 2025

Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies.

Overcoming resistance to antibody-drug conjugates: mechanisms and emerging strategies.

Journal: The oncologist

Published: July 01, 2025

Humoral immunity after hematopoietic stem cell transplantation: evaluation by B-cell receptor repertoire analysis.

Humoral immunity after hematopoietic stem cell transplantation: evaluation by B-cell receptor repertoire analysis.

Journal: International journal of hematology

Published: May 15, 2025

Importance of E/e' and BNP for early detection of late cardiotoxicity in long-term follow-up of childhood hematologic cancer survivors: a retrospective cross-sectional study.

Importance of E/e' and BNP for early detection of late cardiotoxicity in long-term follow-up of childhood hematologic cancer survivors: a retrospective cross-sectional study.

Journal: Cardio-oncology (London, England)

Published: March 21, 2025

Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d).

Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d).

Journal: Frontiers in immunology

Published: July 22, 2024

Corrigendum to 'A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody': [ESMO Open volume 9 issue 6 (2024) 103476].

Corrigendum to 'A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody': [ESMO Open volume 9 issue 6 (2024) 103476].

Journal: ESMO open

Published: July 21, 2024

A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.

A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.

Journal: ESMO open

Published: January 30, 2024

Analysis of B-cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines.

Analysis of B-cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines.

Journal: EJHaem

Published: January 23, 2024

Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration.

Response to mRNA SARS-CoV-2 vaccination evaluated by B-cell receptor repertoire after tixagevimab/cilgavimab administration.

Journal: British journal of haematology

Published: March 22, 2023

GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance.

GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance.

Journal: EJHaem

Published: July 23, 2022

Showing 1-12 of 23

Last Updated: 09/26/2026